These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 19065360)

  • 1. Evaluating nuchal translucency scans performed for trisomy screening in a district general hospital between July 1998 and January 2004.
    MacRae R; Ojutiku D; Duke-MacRae J; Usifo F; Ekong M
    J Obstet Gynaecol; 2008 Oct; 28(7):683-7. PubMed ID: 19065360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuchal translucency in pregnancies conceived after assisted reproduction technology.
    Hui PW; Lee CP; Tang MH; Ho PC
    Curr Opin Obstet Gynecol; 2006 Jun; 18(3):319-24. PubMed ID: 16735833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Wright D; Maiz N; Pandeva I; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Sep; 32(4):488-92. PubMed ID: 18726925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First trimester Down's syndrome screening marker values and cigarette smoking: new data and a meta-analysis on free beta human chorionic gonadotophin, pregnancy-associated plasma protein-A and nuchal translucency.
    Bestwick JP; Huttly WJ; Wald NJ
    J Med Screen; 2008; 15(4):204-6. PubMed ID: 19106261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Quality of nuchal transluccency measurements: an exploratory study into their performance and evaluation].
    van den Berg M; Kleinveld JH; Sander MJ; van Vugt JM; Timmermans DR
    Ned Tijdschr Geneeskd; 2005 Jul; 149(30):1691-6. PubMed ID: 16104116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contingent screening for Down syndrome--results from the FaSTER trial.
    Cuckle HS; Malone FD; Wright D; Porter TF; Nyberg DA; Comstock CH; Saade GR; Berkowitz RL; Ferreira JC; Dugoff L; Craigo SD; Timor IE; Carr SR; Wolfe HM; D'Alton ME
    Prenat Diagn; 2008 Feb; 28(2):89-94. PubMed ID: 18236423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuchal translucency and first-trimester screening.
    Harry WG; Reed KL
    J Soc Gynecol Investig; 2006 Apr; 13(3):153-4. PubMed ID: 16638584
    [No Abstract]   [Full Text] [Related]  

  • 8. [Prenatal diagnosis of chromosome aberrations after implementation of screening for Down's syndrome].
    Kjaergaard S; Hahnemann JM; Skibsted L; Jensen LN; Sperling L; Zingenberg H; Kristiansen A; Brøndum-Nielsen K
    Ugeskr Laeger; 2008 Mar; 170(14):1152-6. PubMed ID: 18405480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of standardization in determining gestational age for prenatal screening.
    Koster MP; Van Leeuwen-Spruijt M; Wortelboer EJ; Stoutenbeek P; Elvers LH; Loeber JG; Visser GH; Schielen PC
    Ultrasound Obstet Gynecol; 2008 Oct; 32(5):607-11. PubMed ID: 18720453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. "Holding our breath": the experiences of women contemplating nuchal translucency screening.
    Hawthorne F; Ahern K
    Appl Nurs Res; 2009 Nov; 22(4):236-42. PubMed ID: 19875037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The utility of detailed first trimester ultrasound examination in abnormal fetal nuchal translucency.
    Bronshtein M; Zimmer EZ; Blazer S
    Prenat Diagn; 2008 Nov; 28(11):1037-41. PubMed ID: 18925580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Molecular biology usefulness for rapid diagnosis of Down's syndrome and common aneuploidies].
    Fauret AL; Bilan F; Patri S; Couet D; Marechaud M; Pierre F; Gilbert-Dussardier B; Kitzis A
    Gynecol Obstet Fertil; 2009; 37(7-8):611-9. PubMed ID: 19574080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuchal translucency screening: how do women actually utilize the results?
    Caughey AB; Musci TJ; Belluomini J; Main D; Otto C; Goldberg J
    Prenat Diagn; 2007 Feb; 27(2):119-23. PubMed ID: 17152116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A.
    Kagan KO; Wright D; Valencia C; Maiz N; Nicolaides KH
    Hum Reprod; 2008 Sep; 23(9):1968-75. PubMed ID: 18544579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prenatal screening for serious congenital heart defects using nuchal translucency: a meta-analysis.
    Wald NJ; Morris JK; Walker K; Simpson JM
    Prenat Diagn; 2008 Dec; 28(12):1094-104. PubMed ID: 19009556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Education and quality review for nuchal translucency ultrasound.
    D'Alton ME; Cleary-Goldman J
    Semin Perinatol; 2005 Dec; 29(6):380-5. PubMed ID: 16533651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuchal translucency thickness in euploid fetuses: is two millimeters too risky?
    Fink M; Sheiner E; Sheizaf B; Hershkovitz R; Bashiri A; Mazor M; Wiznitzer A
    Am J Perinatol; 2009 Apr; 26(4):303-7. PubMed ID: 19031359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined test + inhibin A at week 13 in contingent sequential testing: an interesting alternative for first-trimester prenatal screening for Down syndrome.
    Ramos-Corpas DJ; Santiago JC
    Prenat Diagn; 2008 Sep; 28(9):833-8. PubMed ID: 18661488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple-marker screening for Down's syndrome: a method of assessing the statistical robustness of proposed tests.
    Morris JK; Bestwick J; Wald NJ
    J Med Screen; 2008; 15(2):55-61. PubMed ID: 18573771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prenatal diagnostics in Arhus and Viborg Counties after implementation of first trimester risk assessment].
    Tørring N; Jølving LR; Petersen OB; Holmskov A; Hertz JM; Uldbjerg N
    Ugeskr Laeger; 2008 Jan; 170(1):50-4. PubMed ID: 18208717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.